Accepted answer
The short version: real savings on carriage and unit price, real risks in custody, splitting and the legal position of whoever receives it.
The real saving is in carriage and in unit price breaks, not in the compound itself. Carriage on a single larger consignment is typically a fraction of the sum of individual shipments, and that is where most of the arithmetic comes from.
Cost per milligram, adjusted honestly
| Step | Value | Note |
|---|
| Vial price, 10 mg nominal | £34.00 | As advertised |
| Nominal cost per mg | £3.40 | 34 ÷ 10 |
| Measured content | 9.2 mg | Independent content assay |
| Cost per actual mg | £3.70 | 34 ÷ 9.2 |
| Dead-space loss, 20 draws | 4 % | 80 µL of a 2 mL fill |
| Cost per delivered mg | £3.85 | 3.70 ÷ 0.96 |
| First vial, with £110 assay | £14.85 | Testing dominates a single vial |
Whoever receives the consignment is the importer of record in most jurisdictions, regardless of who paid. That is a legal position rather than an administrative one and it does not divide among contributors.
Importer-of-record status attaches to the receiving party in most customs regimes and is not divisible among contributors.
The caveat is legal rather than analytical: onward supply is treated differently from personal importation in many jurisdictions and the difference is not a technicality.
Split sealed vials only. Anything else breaks the certificate and the closure together.
edited 26 Mar 2025 by thabo_maseko — reworded for clarity after a comment